Adial Pharmaceuticals to expand ADO4 for potential use for opioid disorder

Adial Pharmaceuticals announced plans to expand activities around the company’s lead asset, AD04, beyond alcohol use disorder, or AUD, to now include its potential use in patients with opioid use disorder. According to the Centers for Disease control, in 2017 alone, more than 72,000 people in the U.S. died of drug overdoses, at least two-thirds of which were linked to opioids.

https://thefly.com/landingPageNews.php?id=2836603